Indication
Study
Status
Learn More
AQST-108
Allergy
Safety-tolerability and pharmacokinetics of ascending single doses of AQST-108 in healthy young male volunteers.
Completed
AQST-108
Allergy
A Phase 1, Single-Center, Open-Label, 7-Period, 4-Treatment (with Replication of Three Treatments), 3-Sequence Crossover Study to Compare The Pharmacokinetics and Pharmacodynamics of Epinephrine Administered as AQST-108 to That of Epinephrine Administered at 2 Different Dose Levels of a Subcutaneous Injection and 1 Dose Level of an Intramuscular Injection In Healthy Adult Subjects
Completed
AQST-109
Allergy
A Phase 1, Randomized Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of Sublingual Drops and 4 Formulations of AQST-109 in Healthy Young Male Volunteers
Completed
AQST-109
Allergy
A Phase 1, Single-Center, Randomized, Open-Label, 3-Part Adaptive Design, Crossover Study to Compare the Pharmacokinetics and Pharmacodynamics of Epinephrine Following Administration of AQST-109 and Epinephrine Administered as Intramuscular Injection in Healthy Adult Volunteers
Completed
AQST-109
Allergy
A Phase I, Single-Center, Open-Label, Randomized Study to Compare the Pharmacokinetics and Pharmacodynamics of Epinephrine Administered to Healthy Adult Subjects as a Single or Repeated Dose of AQST-109, or by Intramuscular Injection, via either EpiPen® 0.3mg (Single Dose), or a Single or Repeated Standard 0.3mg Injection
Completed